Literature DB >> 15570257

Re: Imatinib mesylate administration in the first 100 days after stem cell transplantation.

Paolo Anderlini, Sheetal Sheth, Krystal Hicks, Cindy Ippoliti, Sergio Giralt, Richard E Champlin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15570257     DOI： 10.1016/j.bbmt.2004.09.004

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN： 1083-8791            Impact factor:   5.742


× No keyword cloud information.
  17 in total

Review 1.  New approaches to the management of Philadelphia-chromosome-positive acute lymphocytic leukemia.

Authors:  Deborah A Thomas; Susan O'Brien; Jorge Cortes; Hagop Kantarjian
Journal:  Curr Hematol Malig Rep       Date:  2007-07       Impact factor: 3.952

2.  Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia.

Authors:  Paul A Carpenter; David S Snyder; Mary E D Flowers; Jean E Sanders; Theodore A Gooley; Paul J Martin; Frederick R Appelbaum; Jerald P Radich
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

3.  Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia.

Authors:  Veronica Leoni; Andrea Biondi
Journal:  Haematologica       Date:  2015-03       Impact factor: 9.941

4.  The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia.

Authors:  Vivian G Oehler; Ted Gooley; David S Snyder; Laura Johnston; Allen Lin; Carrie C Cummings; Su Chu; Ravi Bhatia; Stephen J Forman; Robert S Negrin; Frederick R Appelbaum; Jerald P Radich
Journal:  Blood       Date:  2006-10-24       Impact factor: 22.113

5.  Allogeneic stem cell transplantation for chronic myeloid leukemia resistant to tyrosine kinase inhibitors.

Authors:  Richard Champlin; Elias Jabbour; Partow Kebriaei; Paolo Anderlini; Borje Andersson; Marcos de Lima
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2011-04-28

6.  Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes.

Authors:  Partow Kebriaei; Rima Saliba; Gabriela Rondon; Alexandre Chiattone; Rajyalakshmi Luthra; Paolo Anderlini; Borje Andersson; Elizabeth Shpall; Uday Popat; Roy Jones; Laura Worth; Farhad Ravandi; Deborah Thomas; Susan O'Brien; Hagop Kantarjian; Marcos de Lima; Sergio Giralt; Richard Champlin
Journal:  Biol Blood Marrow Transplant       Date:  2011-08-23       Impact factor: 5.742

Review 7.  Role of tyrosine kinase inhibitors in the management of Philadelphia chromosome-positive acute lymphoblastic leukemia.

Authors:  Michael S Mathisen; Susan O'Brien; Deborah Thomas; Jorge Cortes; Hagop Kantarjian; Farhad Ravandi
Journal:  Curr Hematol Malig Rep       Date:  2011-09       Impact factor: 3.952

Review 8.  The role of allogeneic stem cell transplantation for CML in the tyrosine kinase inhibitor era.

Authors:  Corey Cutler; Joseph H Antin
Journal:  Curr Hematol Malig Rep       Date:  2006-09       Impact factor: 3.952

Review 9.  Treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

Authors:  Ryuzo Ohno
Journal:  Curr Oncol Rep       Date:  2008-09       Impact factor: 5.075

Review 10.  Philadelphia chromosome-positive acute lymphoblastic leukemia.

Authors:  Farhad Ravandi; Partow Kebriaei
Journal:  Hematol Oncol Clin North Am       Date:  2009-10       Impact factor: 3.722
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.